122 related articles for article (PubMed ID: 23676999)
1. [Proteome profiling for the identification of lung cancer signatures].
Cho WC
Zhongguo Fei Ai Za Zhi; 2012 Jul; 15(7):C4-7. PubMed ID: 23676999
[TBL] [Abstract][Full Text] [Related]
2. Lung cancer signatures in plasma based on proteome profiling of mouse tumor models.
Taguchi A; Politi K; Pitteri SJ; Lockwood WW; Faça VM; Kelly-Spratt K; Wong CH; Zhang Q; Chin A; Park KS; Goodman G; Gazdar AF; Sage J; Dinulescu DM; Kucherlapati R; Depinho RA; Kemp CJ; Varmus HE; Hanash SM
Cancer Cell; 2011 Sep; 20(3):289-99. PubMed ID: 21907921
[TBL] [Abstract][Full Text] [Related]
3. Is proteomics starting to deliver on biomarkers discovery.
Admon A
Pigment Cell Melanoma Res; 2011 Dec; 24(6):1084-5. PubMed ID: 22216444
[No Abstract] [Full Text] [Related]
4. Nkx2-1: a novel tumor biomarker of lung cancer.
Yang L; Lin M; Ruan WJ; Dong LL; Chen EG; Wu XH; Ying KJ
J Zhejiang Univ Sci B; 2012 Nov; 13(11):855-66. PubMed ID: 23125078
[TBL] [Abstract][Full Text] [Related]
5. [Diagnosis value of serum NKX2-1 for primary lung cancer].
Yang L; Ruan WJ; Chen EG; Ying KJ
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2012 Sep; 41(5):535-9. PubMed ID: 23086646
[TBL] [Abstract][Full Text] [Related]
6. Case of anti-transcriptional intermediary factor-1-positive dermatomyositis associated with breast cancer developing over 10 years.
Matsushita T; Takehara K; Oishi K; Maeda S; Hamaguchi Y; Ishikawa S; Inokuchi M; Michiwa Y; Takehara K
J Dermatol; 2017 Aug; 44(8):972-973. PubMed ID: 27607893
[No Abstract] [Full Text] [Related]
7. Identification of potential erythrocyte phospholipid fatty acid biomarkers of advanced lung adenocarcinoma, squamous cell lung carcinoma, and small cell lung cancer.
Sánchez-Rodríguez P; Rodríguez MC; Sánchez-Yagüe J
Tumour Biol; 2015 Jul; 36(7):5687-98. PubMed ID: 25702090
[TBL] [Abstract][Full Text] [Related]
8. Serum microRNA-365 in combination with its target gene TTF-1 as a non-invasive prognostic marker for non-small cell lung cancer.
Liu Y; Zhang G; Li H; Han L; Fu A; Zhang N; Zheng Y
Biomed Pharmacother; 2015 Oct; 75():185-90. PubMed ID: 26337230
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers in the lung cancer diagnosis: a clinical perspective.
Li X; Asmitananda T; Gao L; Gai D; Song Z; Zhang Y; Ren H; Yang T; Chen T; Chen M
Neoplasma; 2012; 59(5):500-7. PubMed ID: 22668014
[TBL] [Abstract][Full Text] [Related]
10. [Correlation between Serum Tumor Markers and Efficacy of First-line EGFR-TKIs in Patients with Advanced Lung Adenocarcinoma].
Chen H; Yang X; Liu H; Ma K; Zhong J; Dong Z; Zhuo M; Wang Y; Li J; An T; Wu M; Wang Z; Zhao J
Zhongguo Fei Ai Za Zhi; 2017 Sep; 20(9):589-597. PubMed ID: 28935011
[TBL] [Abstract][Full Text] [Related]
11. [Variation of serum thyroid transcription factor-1 protein and its value in the diagnosis of lung carcinoma].
Li X; Wan LY; Shen H; Bai XY
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Sep; 31(9):1592-6. PubMed ID: 21945775
[TBL] [Abstract][Full Text] [Related]
12. [Programmed death receptor-l/ligand-1 inhibitors in treatemtn of advanced lung cancer].
Wang Y; Zhou YZ; Li WM
Zhonghua Jie He He Hu Xi Za Zhi; 2018 Oct; 41(10):806-809. PubMed ID: 30347555
[No Abstract] [Full Text] [Related]
13. Mass spectrometric identification, characterization and validation of the haptoglobin β-chain protein as a lung cancer serum biomarker.
Ayyub A; Saleem M; Musharraf SG; Naz M; Tariq A; Hashmi N
Mol Med Rep; 2015 Sep; 12(3):3755-3762. PubMed ID: 26005016
[TBL] [Abstract][Full Text] [Related]
14. An approach of selecting appropriate markers from the primary tumor to enable detection of circulating tumor cells in patients with non-small cell lung cancer.
Warawdekar UM; Sirajuddin MM; Pramesh CS; Mistry RC
J BUON; 2015; 20(3):782-90. PubMed ID: 26214631
[TBL] [Abstract][Full Text] [Related]
15. Serum proteomic profiling of lung cancer in high-risk groups and determination of clinical outcomes.
Jacot W; Lhermitte L; Dossat N; Pujol JL; Molinari N; Daurès JP; Maudelonde T; Mangé A; Solassol J
J Thorac Oncol; 2008 Aug; 3(8):840-50. PubMed ID: 18670301
[TBL] [Abstract][Full Text] [Related]
16. Pulmonary adenocarcinoma: a renewed entity in 2011.
Kadara H; Kabbout M; Wistuba II
Respirology; 2012 Jan; 17(1):50-65. PubMed ID: 22040022
[TBL] [Abstract][Full Text] [Related]
17. Association between serum biomarkers CEA and LDH and response in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
de Jong C; Deneer VHM; Kelder JC; Ruven H; Egberts TCG; Herder GJM
Thorac Cancer; 2020 Jul; 11(7):1790-1800. PubMed ID: 32383328
[TBL] [Abstract][Full Text] [Related]
18. Rapid increase of serum neuron specific enolase level and tachyphylaxis of EGFR-tyrosine kinase inhibitor indicate small cell lung cancer transformation from EGFR positive lung adenocarcinoma?
Zhang Y; Li XY; Tang Y; Xu Y; Guo WH; Li YC; Liu XK; Huang CY; Wang YS; Wei YQ
Lung Cancer; 2013 Aug; 81(2):302-5. PubMed ID: 23683536
[TBL] [Abstract][Full Text] [Related]
19. Preliminary investigation of the clinical significance of detecting circulating tumor cells enriched from lung cancer patients.
Wu C; Hao H; Li L; Zhou X; Guo Z; Zhang L; Zhang X; Zhong W; Guo H; Bremner RM; Lin P
J Thorac Oncol; 2009 Jan; 4(1):30-6. PubMed ID: 19096303
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of serum EGFR gene mutation and serum tumor markers in predicting tyrosine kinase inhibitor efficacy in lung adenocarcinoma.
Feng LX; Wang J; Yu Z; Song SA; Zhai WX; Dong SH; Yu HS; Zhang Y
Clin Transl Oncol; 2019 Aug; 21(8):1005-1013. PubMed ID: 30637712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
